Tom MalinowskiSell
CELC Common Stock · Transaction May 26, 2021 · Filed Jun 23, 2021 · Amount pending receipt enrichment
NASDAQ NMS - GLOBAL MARKET · CELC
+0.46% · +$0.4300 · Vol 771.9K
After hours · updated 16:44:50 ET
Celcuity Inc
Biotechnology
$92.92
Veridion Score
BETALOW CONF · 6/6 factorsStale score · Tue Aug 4 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET · CELC
MethodologyCELC
Celcuity Inc
Stale score · Tue Aug 4 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
SELL BIAS
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
34/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Stale score · Tue Aug 4 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is CELC moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Celcuity Inc
SERVICES-MEDICAL LABORATORIESListed since
2017
Employees
155
Country
US
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$93.68
Day high
$94.41
Day low
$90.82
Previous close
$92.49
52W high
$144.98
-35.91% from high
52W low
$42.84
49% of range
Market cap
$4.5B
EPS
$-3.7900
Beta
1.05
Shares out
48.8M
Volume
771.9K
0.48× rel vol
Avg volume
1.6M
VWAP
$92.84
Price history computed in-house
1W
+11.60%
1M
-14.42%
3M
-28.91%
1Y
+116.90%
YTD
-6.84%
SMA 50 $97.58 · below
SMA 200 $104.34 · below
52W position 49%
CELC overview
Veridion Score
34
6 of 6 factors measured
Congress receipts
4
Tom Malinowski · Sale
13F holders
None on file
Related filings and maps
Public disclosures
Congress activity in CELC
Official filing ↗
CELC Common Stock · Transaction Jun 23, 2020 · Filed Aug 26, 2021 · Amount pending receipt enrichment
CELC Common Stock · Transaction Jun 22, 2020 · Filed Aug 26, 2021 · Amount pending receipt enrichment
CELC Common Stock · Transaction Jun 18, 2020 · Filed Mar 5, 2021 · Amount pending receipt enrichment
Federal contracts
CELC contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CELC in this window.
Lobbying spend
CELC lobbying filings, year to date.
Registered lobbying filings matched to Celcuity Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CELC in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for CELC.
Options
Sovereign unlock shows live options positioning for CELC.